Did you use Dupixent to treat a skin condition such as eczema or atopic dermatitis, and later receive a diagnosis of Cutaneous T-Cell Lymphoma (CTCL)? You may be entitled to compensation. Find out today if your case qualifies.

 At Garn & Graber, we are investigating whether the use of Dupixent for skin conditions like eczema or atopic dermatitis, potential risks associated with the medication, or a lack of sufficient warnings about its adverse effects, may have contributed to the development of Cutaneous T-Cell Lymphoma (CTCL). 

This has resulted in complex medical treatments, a significant impact on health and quality of life, and other complications associated with the disease.

You may qualify if:

• You used Dupixent to treat a skin condition.
• You were subsequently diagnosed with Cutaneous T-Cell Lymphoma (CTCL).
• This condition has impacted your health or required medical treatment.

Every case is reviewed individually.

If you believe you may have been harmed by your use of Dupixent, contact us today for a free and confidential case evaluation.